|
ATTENTION
PPH PATIENTS |
Patients suffering from Primary
Pulmonary Hypertension (PPH) caused by
Fen-Phen are NOT involved
in the Nationwide Class Action Settlement Agreement
with American Home Products. PPH patients must
file independent lawsuits to make legal claims.
To learn your legal rights, please contact
us and speak with a PPH Lawyer for
lawsuit information! |
|
|
FEN PHEN CLAIMS
DEADLINE:
AUGUST 2002
|
| Numerous
former fen phen patients are now suffering the serious
and fatal condition called primary
pulmonary hypertension (PPH). An estimated 6 million
to 7 million people in the U.S. have taken fen phen. On
January 11, 2002 the fen phen Settlement became final.
If you have used the diet drug fen phen, also marketed
under the names Redux and Pondimin, you are eligible to
file a claim by August 2002. CONTACT
US so that you can receive the compensation that is
rightfully yours. |
FDA Withdrawal of Fenfluramine and Dexfenfluramine
(Fen Phen) Announcement
FOR IMMEDIATE RELEASE
September 15, 1997
FDA ANNOUNCES WITHDRAWAL OF
FENFLURAMINE AND DEXFENFLURAMINE
The Food and Drug Administration,
acting on new evidence about significant side-effects associated
with fenfluramine and dexfenfluramine, has asked the manufacturers
to voluntarily withdraw both treatments for obesity from the
market. Dexfenfluramine is manufactured for Interneuron Pharmaceuticals
and marketed under the name of Redux by Wyeth-Ayerst Laboratories,
a subsidiary of American Home Products Corp. of Madison, N.J.,
which also manufactures and markets fenfluramine under the
brand name Pondimin. Both companies have agreed to voluntarily
withdraw their drugs. The FDA is not requesting the withdrawal
of phentermine, the third widely used medication for obesity.
read
the full story >
top
of page
Fen Phen Settlement
American Home Products (AHP) withdrew
popular diet drug fen phen from the market on September 15,
1997. The once deemed "miracle drug" took off with
an immediate 18,000,000 prescriptions written in 1996 and
in the U.S. there are estimates that between 6 million and
7 million people took fen phen.
Fen phen did not live up to its name,
though, as reports of a serious and fatal condition called
primary
pulmonary hypertension (PPH) began to surface. But evidence
of the serious and fatal health
complications fen phen could cause were available well
prior to the FDA withdrawal. In a 1996 study published in
The New England Journal of Medicine, it concluded that there
is a twenty-three-fold increase in the risk of developing
PPH when using fen phen for more than three months.
read
the full story >
top
of page
|
Nationwide Class Action Settlement
Agreement
::::::::::::::::::::::::::::::::: |
American Home Products Corporation has
received Final Judicial Approval as of January 3, 2002 regarding
their once popular diet drug fen phen. This settlement
has beenthe result of the serious health
complications fen phen use has been directly linked to like
primary pulmonary hypertension (PPH).
Primary
pulmonary hypertension is a serious and potentially life
threatening cardiovascular condition, and a 1996 study published
in The New England Journal of Medicine found a twenty-three-fold
increase in the risk of developing PPH when using fen phen
for more than three months. In 1996 alone there were 18,000,000
prescriptions written for the appetite suppressant fen phen,
and in the U.S. there are estimates that between 6 million
and 7 million people took fen phen.
Final judicial approval means that
anyone who has sustained the deadly phentermine side effects
can now collect their claims if eligible. Please
contact us for more information regarding your benefit eligibility
and to speak to a PPH attorney.
top
of page
About Primary Pulmonary Hypertension
(PPH)
"It's a very
rare disease (PPH), that tends to affect women in their 30s.
After diagnosis, patients are typically dead within two years."
-Dr. Sean Gaine, director of the
pulmonary hypertension center at John Hopkins Medical Center
in Boston.
Primary pulmonary hypertension
(PPH) is a serious and potentially life threatening cardiovascular
condition that is not curable. A study published in the New
England Journal of Medicine in August 1996 found that the
use of fen phen for three months or longer is associated with
a twenty-three fold increase in the risk of developing primary
pulmonary hypertension. PPH causes high blood pressure
in the lungs that leads to a feeling of constant breathlessness
with minimal exertion, fatigue, dizzy spells, fainting, and
chest pain. There is no known cause of PPH but it has been
the direct result of the use of the once popular diet drug
fen phen, or phentermine.
read
the full story >
top
of page
Fen Phen Information
Dr. Michael Weintraub developed fen
phen while working as a researcher at the University of Rochester.
The phentermine and pondimin combination in a low dose was
found to suppress appetite to fuel weight loss and have fewer
side effects then when the drugs were taken individually.
The weight loss drug combination was termed fen phen, and
the drug's popularity was immediate. In 1996 alone there were
18,000,000 prescriptions written for the appetite suppressant
fen phen.
read
the full story >
top
of page
|
